Medicover AB (publ)

Medicover AB (publ)

MCVEF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.29B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Medicover AB (publ)Medicover AB (publ)39.80.84%17%1.82.4

Earnings Call Q3 2026

November 4, 2026 - AI Summary

Strong Q3 momentum (continuing operations): growth + margin accretion - Organic revenue growth +8% (total revenue +6%), with ~2% negative FX impact. - EBIT +22% YoY (margin rate improved +110 bps YoY) to EUR 49.3m. - EBITDA +7.1% YoY to EUR 70.9m (rate up +70 bps YoY); EPS just over EUR 0.16. - Adjusted EBITDA margin improved (reported trend 17.6% → 17.8%) and leverage down to 2.7; ROIC improved to 14% (from 13%).
Operational drivers: fee-for-service strength + Sports & Wellness; diagnostics improving mix; pockets of weakness - Healthcare Services: organic revenue +8%; pricing ~6%; FX ~1.9%; margin expansion (EBITDA up ~70–90 bps YoY). - Sports & Wellness: continued strength; leadership expects acceleration of openings into Q4 and beyond (also used as an “alternative membership base”). - Diagnostics: organic revenue +8.5% (about 50/50 price vs volume); fee-for-service strengthening supports pricing control; margin in diagnostics roughly flat YoY (reported 14.3% EBITDA margin, ~down 20 bps), mainly due to Germany softness and Genetics offset by stronger Poland/Romania/SSE. - Commentary suggests some near-term volume softness relates to phasing/cycle effects (especially B2B decision cycles and prior pricing stance), not a collapse in demand.
India divestment: major capital event improving strategic flexibility (closing targeted for Nov/Q4) - Medicover decided to divest India for EUR 1.2bn enterprise value; Medicover’s shareholding 66.1% implies cash proceeds of ~EUR 740m. - Expected close in November or Q4; 100% sold by Medicover + local partners (full exit). - Management signals proceeds will be focused on core countries and reshaping strategy; no detailed allocation plan given yet (to be discussed post-close).

Exclusive for Stockcircle Pro members

Sign upSign Up
$13.20

Current Fair Value

53.3% downside

Overvalued by 53.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$4.29 Billion
Enterprise Value$5.50 Billion
Annual dividend$0.23
Dividend yield0.84%
Earnings per Share$0.51
Beta1.5
Outstanding Shares151,974,274

Return

Return on Equity16.88%ROE
Return on Assets3.74%
Return on Invested Capital13.26%

Valuation & Multiples

P/E Ratio39.84P/E Ratio
PEG131.4PEG
Price to Sales1.77Price to Sales
Price to Book Ratio9.42Price to Book Ratio
Enterprise Value to Revenue2.25
Enterprise Value to EBIT30.77
Enterprise Value to Net Income60
Total Debt to Enterprise0.23
Debt to Equity2.39Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 4, 2026
EPS
$0.18
Est. $0.19
Revenue
$646.63 M
Est. $681.75 M

Next Earnings Call

Expected Date
February 10, 2027
EPS Estimate
$0.16
Consensus analyst estimate
Revenue Estimate
$667.42 M
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Medicover AB (publ)

49,000 employees
CEO: John Paul Stubbington

Medicover AB (publ) delivers healthcare and diagnostic solutions across multiple countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. The company operates through...